Last reviewed · How we verify
NCT05409924
First-in-human Single and Multiple Dose Trial of ATR-258
Phase 1 trial testing ATR-258 in Type 2 Diabetes Mellitus in 71 participants. Completed in 4 October 2023.
4 October 2023
Quick facts
| Lead sponsor | Atrogi AB |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 71 |
| Start date | 11 April 2022 |
| Primary completion | 4 October 2023 |
| Estimated completion | 4 October 2023 |
| Sites | 1 location across Germany |
Drugs / interventions tested
Conditions studied
- Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Sponsor
Atrogi AB — full company profile →
Who can join
Adults 18 to 55, male only, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-site, randomized, double-blinded, placebo-controlled, First-in-Human trial, conducted in 3 parts.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.
Motso A, Pelcman B, Kalinovich A, Kahlous NA, et al · · 2025 · cited 4× · PMID 40882626 · DOI 10.1016/j.cell.2025.08.022 -
When rehabilitation is not enough, how targeting metabolism can overcome the limited plasticity of skeletal muscle after traumatic injury.
Greising SM, Call JA. · · 2026 · PMID 41264541 · DOI 10.1113/ep093074
Verify or expand the search:
- PubMed search for NCT05409924
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ATR-258
Trials testing the same drug.
- NCT07421024 — Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle · Phase 2 · not yet recruiting
Other recruiting trials for Type 2 Diabetes Mellitus
Currently open trials in the same condition.
- NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
- NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
- NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
- NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
- NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting
Other Atrogi AB trials
Trials by the same sponsor.
- NCT06432673 — The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05409924 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Atrogi AB
- Last refreshed: 18 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05409924.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing